Lower back surgery represents a life-changing decision that demands careful consideration. While many view surgery as a ...

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on FibroBiologics, Inc. (FBLG – Research Report) today and set a price ...

The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face ...

Strengthening research in retinal disease with record-breaking ... underscores its commitment to advancing treatments and potential cures for retinal degenerative diseases that affect millions ...

driving progress in treatment approaches from gene-agnostic therapies to those targeting specific genetic causes, such as retinitis pigmentosa, Usher syndrome, Leber congenital amaurosis, Stargardt ...

BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) announced the company’s 3Q 2024 financial results and while a company at this stage is far more reliant on testing of products, ...

The Foundation Fighting Blindness , the driving force in the global development of treatments and ... Stargardt disease, and dry age-related macular degeneration. Within this year's funding ...

For the quarter ended September 30, 2024, the Company had a loss from operations of $2.3 million, a 26% year-over-year improvement from $3.1 million for the comparable period of 2023, and a 9% ...

Nov. 15, 2024 — More time spent sitting, reclining or lying down during the day may increase the risk of cardiovascular disease (CVD) and death, according to a new study. More than roughly 10 ...

and cures for retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease and the entire spectrum of retinal degenerative diseases. The Foundtion Fighting Blindness, Inc. is a ...

The high-quality studies showed that thermal RFA of the DRG is not effective in the treatment of chronic lumbar radicular pain. The trial results provided inconclusive evidence of the efficacy of ...